Short Interest in Femasys Inc. (NASDAQ:FEMY) Expands By 64.2%

Femasys Inc. (NASDAQ:FEMY) was the recipient of a significant growth in short interest during the month of August. As of August 14th, there was short interest totaling 434,999 shares, a growth of 64.2% from the July 30th total of 264,928 shares. Currently, 5.6% of the company’s stock are sold short. Based on an average daily trading volume, of 274,553 shares, the days-to-cover ratio is currently 1.6 days.

Femasys Stock Up 7.2%

Shares of FEMY traded up $0.23 on Monday, hitting $3.43. The company’s stock had a trading volume of 227,000 shares, compared to its average volume of 302,278. The company has a quick ratio of 0.55, a current ratio of 2.14 and a debt-to-equity ratio of 0.89. The firm’s fifty day moving average price is $3.25 and its 200-day moving average price is $6.72. Femasys has a fifty-two week low of $2.02 and a fifty-two week high of $22.20. The firm has a market capitalization of $28.73 million, a price-to-earnings ratio of -0.97 and a beta of -2.08.

Femasys (NASDAQ:FEMY) last released its earnings results on Friday, August 14th. The company reported ($1.33) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.31) by ($0.02). Femasys had a negative return on equity of 225.97% and a negative net margin of 534.36%.The firm had revenue of $0.33 million for the quarter, compared to the consensus estimate of $0.73 million.

Insider Activity

In related news, CEO Kathy Lee-Sepsick bought 15,625 shares of the business’s stock in a transaction on Friday, August 7th. The shares were bought at an average cost of $3.20 per share, for a total transaction of $50,000.00. Following the completion of the acquisition, the chief executive officer directly owned 15,625 shares in the company, valued at approximately $50,000. This represents a ? increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Dov Elefant purchased 15,625 shares of Femasys stock in a transaction on Friday, August 7th. The stock was bought at an average cost of $3.20 per share, with a total value of $50,000.00. Following the transaction, the chief financial officer directly owned 15,625 shares of the company’s stock, valued at approximately $50,000. The trade was a ? increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last 90 days, insiders have acquired 38,750 shares of company stock worth $124,000. Corporate insiders own 7.75% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. Kovack Advisors Inc. acquired a new position in Femasys during the fourth quarter worth $27,000. HRT Financial LP acquired a new stake in Femasys in the fourth quarter valued at $30,000. Cetera Investment Advisers bought a new position in shares of Femasys in the 4th quarter valued at about $36,000. Osaic Holdings Inc. bought a new position in shares of Femasys in the 2nd quarter valued at about $45,000. Finally, State Street Corp increased its stake in shares of Femasys by 43.5% during the 4th quarter. State Street Corp now owns 80,869 shares of the company’s stock worth $47,000 after purchasing an additional 24,500 shares during the last quarter. Institutional investors and hedge funds own 65.27% of the company’s stock.

Wall Street Analyst Weigh In

FEMY has been the topic of a number of analyst reports. Weiss Ratings cut Femasys from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, August 17th. Wall Street Zen cut Femasys from a “hold” rating to a “sell” rating in a research note on Saturday, August 22nd. Maxim Group dropped their price target on shares of Femasys to $10.00 and set a “buy” rating for the company in a research note on Friday, August 14th. Finally, Lake Street Capital reduced their price target on Femasys to $10.00 and set a “buy” rating on the stock in a research report on Tuesday, August 18th. Three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $50.00.

About Femasys

Femasys International, Inc is a medical device company focused on the research, development and commercialization of innovative technologies for interventional women’s health applications. The company’s core activities center on creating minimally invasive diagnostic and therapeutic products designed to address uterine cavity evaluation and treatment and to improve outcomes in gynecological care.

The company’s flagship product, the FemVue® hydrosonography system, is a single-use catheter-based device that enhances visualization of the uterine cavity through saline infusion sonography.